Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo

Chinese Medical Journal

Volumn 126, Issue 23, 2013, Pages 4552-4556

  Zhou, Ji Hao ^a   Yao, Yu Shi ^a   Wang, Li Xin ^a   Wang, Jia ^a   Li, Yong Hui ^a   Jiang, Meng Meng ^a   Zhou, Min Hang ^a   Gao, Xiao Ning ^a   Li, Rui Sheng ^b   Wang, Li Li ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

Autologous; Cancer testis antigens; Cytotoxic T lymphocytes; Decitabine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; CD161 ANTIGEN; MELANOMA ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE CONTROL; DRUG MECHANISM; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKEMIA CELL; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84888231093     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130526     Document Type: Article

References (24)

1. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008; 14: 141-151.
2. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother: CII. 2005; 54: 915-925.
3. Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, et al. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother: CII. 2011; 60: 1289-1297.
4. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985-2990.
5. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and-negative myeloid leukemia cell lines. Leukemia Res 2007; 31: 497-506.
6. de Carvalho F, Vettore AL, Inaoka RJ, Karia B, Andrade VC, Gnjatic S, et al. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. Cancer Immun 2011; 11: 1.
7. Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 2009; 7: 58.
8. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS, et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun 2008; 370: 578-583.
9. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007; 13: 3333-3338.
10. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jaeger E, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Res 2010; 34: 899-905.
11. Yan M, Himoudi N, Basu BP, Wallace R, Poon E, Adams S, et al. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine. Cancer Immunol Immunother 2011; 60: 1243-1255.
12. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
13. Trojan A, Rajeswaran R, Montemurro M, Mutsch M, Steffen R. Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination. J Clin Virol 2007; 40: 80-83.
14. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. Journal of immunology (Baltimore, Md: 1950). 1999; 163: 6867-6875.
15. Xia S, Guo Z, Yao Y, Xu X, Yi H, Xia D, et al. Liver stroma enhances activation of TLR3-triggered NK cells through fibronectin. Mol Immunol 2008; 45: 2831-2838.
16. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006; 28: 1089-1098.
17. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006; 66: 1105-1113.
18. Geyer CR. Strategies to re-express epigenetically silenced p15(INK4b) and p21(WAF1) genes in acute myeloid leukemia. Epigenetics 2010; 5: 696-703.
19. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genet 2005; 37: 265-274.
20. Lubbert M, Ruter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012; 97: 393-401.
21. Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Mancini M, et al. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leukemia Lymphoma 2012; 53: 1558-1560.
22. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, et al. Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. Clin Cancer Res 2011; 17: 7058-7066.
23. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918.
24. Qin XY, Li GX, Qin YZ, Wang Y, Wang FR, Liu DH, et al. Quantitative chimerism kinetics in relapsed leukemia patients after allogeneic hematopoietic stem cell transplantation. Chin Med J 2012; 125: 1952-1959.